Announcements Trials
Browse Landscape

Phase

Phase 2 6

Status

Recruiting 2Active not recruiting 2Unknown 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 6Head & Neck 2Gastrointestinal 2Thoracic 1Other solid neoplasm 1NET 1Genitourinary 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 464Melanoma 300Squamous Cell Carcinoma of Head and Neck 234Parkinson Disease 4, Autosomal Dominant Lewy Body 189Neoplasms 185Triple Negative Breast Neoplasms 163Breast Neoplasms 162Neoplasm Metastasis 157Lung Neoplasms 147Colorectal Neoplasms 142Carcinoma, Renal Cell 132Head and Neck Neoplasms 123Stomach Neoplasms 104Ovarian Neoplasms 101Carcinoma, Transitional Cell 92Urinary Bladder Neoplasms 81Pancreatic Neoplasms 81Endometrial Neoplasms 74Carcinoma, Hepatocellular 74Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 49Sarcoma 43Carcinoma 42Glioblastoma 40Small Cell Lung Carcinoma 39Carcinoma, Squamous Cell 39Hodgkin Disease 36Cholangiocarcinoma 35

Interventions

Radiotherapy 10Cisplatin 9pembrolizumab 6Surveys and Questionnaires 6Methods 6Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 5fludarabine 4Papillomavirus Vaccines 4Early Intervention, Educational 4Cyclophosphamide 4Brachytherapy 4durvalumab 3aldesleukin 3Vaccines, Synthetic 3Vaccines 3Sentinel Lymph Node Biopsy 3Radiosurgery 3Radiation 3Platinum 3Palliative Care 3Paclitaxel 3Nivolumab 3Indocyanine Green 3Gemcitabine 3Drug Therapy 3Carboplatin 3Bleomycin 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3tremelimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Vulvar Neoplasms × pembrolizumab × Clear all
NCT05903833 2026-05-11

PIERCE

AGO Research GmbH

Phase 2 Recruiting
42 enrolled
Gynecologic

Vulvar Neoplasms

NCT04430699 2026-05-05

Cisplatin+Pembrolizumab+RT in Vulvar Cancer

Massachusetts General Hospital

Phase 2 Active not recruiting
24 enrolled
Gynecologic

Vulvar Neoplasms

NCT07290894 2026-04-02

MITO VULVA-01

National Cancer Institute, Naples

Phase 2 Recruiting
80 enrolled
Gynecologic

Vulvar Neoplasms

NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 4 FDA
EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04357873 2025-02-19

PEVOsq

UNICANCER

Phase 2 Completed
112 enrolled
GastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Penile Neoplasms, Vulvar Neoplasms, Neoplasms, Squamous Cell

NCT05761132 2023-03-09

Apollo

Leiden University Medical Center

Phase 2 Unknown
40 enrolled
Gynecologic

Vulvar Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡